By Peter A. McCullough, MD, MPH
After five years of being bashed on unsafe, ineffective, uncontrollable Spike protein-producing (Spikevax, mNEXSPIKE) vaccines, Moderna is solidly back home in the cancer business and their stock performance couldn’t be any better.
🧬 The mRNA Cancer Long Game: Moderna’s Pivot from Pandemic to Personalized Chemotherapy
There’s a narrative that’s taken hold in the financial press and biotech cheerleading circles: Moderna, having saved humanity from COVID, is now developing “cancer vaccines” that will do for oncology what Operation Warp Speed did for respiratory viruses.
This is marketing, not medicine.
What Moderna is actually doing is using synthetic messenger RNA as a delivery mechanism for personalized neoantigens as a part of toxic combination chemotherapy. Calling these “vaccines” is a linguistic sleight of hand designed to borrow the halo from childhood immunization while obscuring the reality of what’s being injected into patients’ bodies week after week.
